Trials / Completed
CompletedNCT02734849
Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Allakos Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study to evaluate multiple doses of AK001 across 2 active doses. Pharmacodynamic activity will also be evaluated.
Detailed description
AK001 is a monoclonal antibody which may be useful in the treatment of patients with moderate to severe nasal polyposis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK001 low dose | 25 mg AK001 will be administered as multiple doses |
| DRUG | AK001 high dose | 250 mg AK001 will be administered as multiple doses |
| DRUG | Placebo | Placebo will be administered as multiple doses |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2016-04-12
- Last updated
- 2021-01-25
- Results posted
- 2020-12-28
Locations
15 sites across 6 countries: United States, Belgium, Germany, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02734849. Inclusion in this directory is not an endorsement.